Eindhoven-based deeptech startup Chromodynamics, which creates instruments to improve the speed and accuracy of drug development, focusing on immunotherapy, has secured €2 million in seed funding from KIKK Capital. The investment will enable the startup to complete and launch its microscopy product for biomedical research.
- Founded in 2019 by Wouter Vijvers, Chromodynamics develops advanced multispectral cameras that capture real-time images of material composition.
- Chromodynamics' technology delivers resolution, speed, and spectral range simultaneously, enabling more detailed and efficient analysis.
- The company's solution improves spectral imaging, enabling faster, more accurate data for applications in research, diagnostics, drug development, food production, and manufacturing, boosting efficiency and reducing costs.
Details of the deal
- The seed round came from KIKK Capital, a Dutch-based venture capital firm that supports companies with new products, processes, or services recently introduced to the market.
"As a Deep Tech investor and experienced investor in biotech platform technology, we are well-positioned to support Chromodynamics with our expertise in building successful companies and leveraging our network in the biotech industry,” Managing Partner at KIKK Capital, Johan Sebregts, commented.
- With the fresh capital raised, the startup plans to complete the development of its microscopy product and to commercially launch it into the biomedical research market.
“With the support of KIKK Capital, we have taken a big step towards the launch of a product that brings us closer to that future. And that is what drives our talented team to great heights," founder and CEO of Chromodynamics, Wouter Vijvers, stated.
